BCR-ABL-IN-6 is a selective Bcr-Abl kinase inhibitor used in research on chronic myeloid leukemia; it exhibits potent intracellular affinity for Bcr-Abl kinase with an EC50 of 14.6 nM and shows inhibitory activity against both Bcr-AblWT (IC50 = 4.6 nM) and Bcr-AblT315I (IC50 = 227 nM).